2. Search Result
Search Result
Results for "

CHF

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14399
    Itanapraced
    1 Publications Verification

    CHF5074; CSP-1103

    		 γ-secretase Apoptosis Neurological Disease
    Itanapraced (CHF5074) is an orally active γ-secretase modulator and a non-steroidal anti-inflammatory derivative. Itanapraced reduces Aβ42 and Aβ40 secretion with IC50 values of 3.6 and 18.4 μM, respectively. Itanapraced inhibits cell apoptosis of hippocampal neurons induced by oxygen and glucose deprivation (OGD). Itanapraced can be used for the research of Alzheimer's disease .
    Itanapraced
  • HY-151198
    CHF-6366

    		mAChR Adrenergic Receptor Calcium Channel Inflammation/Immunology Endocrinology
    CHF-6366 is a potent M3 muscarinic antagonist and β2-adrenergic receptors agonist with pKi values of 10.4 and 11.4, respectively. CHF-6366 is also a weak calcium channel inhibitor (IC50~50 μM). CHF-6366 inhibits bronchoconstriction in guinea pigs. CHF-6366 can be used to research chronic obstructive pulmonary disease (COPD) .
    <em>CHF</em>-6366
  • HY-U00302
    CHF5407

    		mAChR Inflammation/Immunology
    CHF5407 is a selective, long-acting and competitive muscarinic M3 receptor antagonist. CHF5407 shows subnanomolar affinities for human muscarinic M1 (hM1), M2 (hM2) and M3 (hM3) receptors. CHF5407 shows a prolonged antibronchospastic activity .
    <em>CHF</em>5407
  • HY-19929
    Tanimilast

    CHF-6001

    		 Phosphodiesterase (PDE) Inflammation/Immunology
    Tanimilast (CHF-6001) is a novel highly potent and selective phosphodiesterase 4 inhibitor(IC50=0.026 ± 0.006 nM) with robust anti-inflammatory activity and suitable for topical pulmonary administration.Tanimilast is used for the research of obstructive lung diseases .
    Tanimilast
  • HY-B0592S
    Trandolapril-d5

    RU44570 D5
    Trandolapril-d5 is a deuterium labeled Trandolapril (RU44570). Trandolapril is an orally active angiotensin converting enzyme (ACE) inhibitor for hypertension and congestive heart failure (CHF)[1].
    Trandolapril-d5
  • HY-B0592
    Trandolapril

    RU44570

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril
  • HY-B0592A
    Trandolapril hydrochloride

    RU44570 hydrochloride

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril hydrochloride
  • HY-18207
    Fasidotril

    Alatriopril

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Fasidotril is a dual inhibitor of neprilysin and angiotensin-converting enzyme (ACE) for the potential research of hypertension and congestive heart failure (CHF).
    Fasidotril
  • HY-118472
    Benazeprilat

    CGS 14831

    		 Drug Metabolite Endogenous Metabolite Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage .
    Benazeprilat
  • HY-120577
    BA 41899

    		Others Cardiovascular Disease
    BA 41899 is a purely calcium-sensitizing agent. BA 41899 is completely devoid of phosphodiesterase (PDE) III inhibitory activity or any other known inotropic mechanism. BA 41899 can be used for the research of cardiovascular diseases, such as congestive heart failure (CHF) .
    BA 41899
  • HY-B0205
    Candesartan
    4 Publications Verification

    CV 11974

    		 Angiotensin Receptor PPAR Cardiovascular Disease Endocrinology Cancer
    Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .
    Candesartan
  • HY-B0205R
    Candesartan (Standard)

    CV 11974 (Standard)

    		 Angiotensin Receptor PPAR Cardiovascular Disease Endocrinology Cancer
    Candesartan (Standard) is the analytical standard of Candesartan. This product is intended for research and analytical applications. Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .
    Candesartan (Standard)
  • HY-123348
    Sampatrilat

    UK-81252

    		 Angiotensin-converting Enzyme (ACE) Neprilysin Cardiovascular Disease Inflammation/Immunology
    Sampatrilat (UK-81252) is a potent and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase (NEP). Sampatrilat inhibits C-domain ACE (Ki=13.8 nM) 12.4-fold more potent than that for the N-domain (Ki=171.9 nM). Sampatrilat (UK-81252) can be used for the study of chronic heart failure and blood pressure regulation .
    Sampatrilat
  • HY-106994
    Nebentan

    YM598 free base

    		 Endothelin Receptor Cardiovascular Disease Inflammation/Immunology
    Nebentan (YM598 free base) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan inhibits [ 125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively . YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo .
    Nebentan
  • HY-106994A
    Nebentan potassium

    YM598

    		 Endothelin Receptor Cardiovascular Disease Inflammation/Immunology
    Nebentan potassium (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan potassium inhibits [ 125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively . YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo .
    Nebentan potassium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: